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S UMMA R Y
The emergence of drug-resistant tuberculosis (TB) is a
challenge to TB control in Europe. We evaluated second-
line drug susceptibility testing in Mycobacterium
tuberculosis isolates from patients with multidrug-
resistant, pre-extensively drug-resistant (pre-XDR-TB)
and XDR-TB at 23 TBNET sites in 16 European
countries. Over 30% of bacilli from patients with pre-
XDR-TB showed resistance to any fluoroquinolone and
almost 70% to any second-line injectable drug. Respec-
tively .90% and .80% of the XDR-TB strains tested
showed phenotypic resistance to pyrazinamide and
ethambutol. Resistance to prothionamide/ethionamide
was high in bacilli from pre-XDR-TB patients (43%)
and XDR-TB patients (49%).
K E Y WORD S : Europe; drug resistance; MDR-TB; TB;
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THE EMERGENCEOF DRUG-RESISTANTstrains
of Mycobacterium tuberculosis is a challenge to
global tuberculosis (TB) control.1 Multidrug-resis-
tant TB (MDR-TB) is defined as in vitro resistance to
at least rifampicin (RMP) and isoniazid (INH). Pre-
extensively drug-resistant TB (pre-XDR-TB) is
defined as additional resistance to either a World
Health Organization (WHO) Group 2 injectable
drug (second-line injectables [SLIs] such as amika-
cin, capreomycin, kanamycin) or a WHO Group 3
fluoroquinolone (FQ).2 In XDR-TB, additional
resistance to at least one drug from both WHO
Groups 2 and 3 is present.2 Treatment outcomes are
directly related to the level of drug resistance in M.
tuberculosis. In a meta-analysis based on 6724 cases,
treatment success was respectively 64%, 56%, 48%
and 40% inMDR-TB, pre-XDR-TB (SLI resistance),
pre-XDR-TB (FQ resistance) and XDR-TB pa-
tients.3 Recent surveillance data from the European
Centre of Disease Prevention and Control (ECDC,
Stockholm, Sweden) showed treatment success in
only 31% of MDR-TB and 19% of XDR-TB
patients in Europe.4 Second-line anti-tuberculosis
drug susceptibility testing (DST) is performed in
only 21% of bacilli from notified MDR-TB patients
in the European Region.4
We evaluated data from a prospective multination-
al observational cohort ofMDR-/XDR-TB patients in
Europe to identify patterns of second-line drug
resistance in M. tuberculosis and risk factors for
pre-XDR and XDR-TB. As part of the European
Union (EU) funded TBPANNET, the present study
was conducted between January 2010 and February
2014 at 23 Tuberculosis Network European Trials
(TBNET; www.tb-net.org) sites specialising in the
care of MDR-/XDR-TB patients in 16 European
countries: 2 high TB incidence (.100 per 100 000
population), 4 intermediate incidence (20–100/
100 000) and 10 low incidence (,20/100 000).5
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METHODS
Patients who provided informed consent and were
started on treatment for a new episode of culture-
confirmed MDR-TB (resistance to at least RMP and
INH) were eligible for enrolment, as described
elsewhere.3 All consecutive MDR-TB patients who
gave consent at each site during the study period were
included in the cohort. Ethics approval was obtained
from the University of Lu¨beck, Lu¨beck, Germany,
and subsequently at other participating sites. An
electronic case record form (www.openclinica.com)
was used for data collection.
Patients were classified as having MDR-TB, pre-
XDR-TB or XDR-TB based on DST results for the
culture-positive sputum specimen obtained closest to
the start of appropriate treatment for this resistance
pattern. All laboratories at the study sites were quality-
controlled by the WHO Supranational Reference
Laboratory Network. Phenotypic testing was per-
formed at all sites using liquid culture, with the
exception of Romania. The frequency of DST and the
proportion of strains classified as resistant are reported
for individual drugs and specific groups of drugs.
Ordinal logistic regression was performed to assess
variables associated with increased drug resistance, in
which the outcome variable was ordered as MDR-,
pre-XDR- and XDR-TB. All included variables were
dichotomised. To align with earlier analyses in the
current cohort and other studies, age was dichotom-
ised at 45 years. Variables were included in a
multivariable model if P , 0.10 in the univariable
model. Odds ratios (ORs) with their associated 95%
confidence intervals (CIs) were calculated. The level
of statistical significance was set at 5%.
RESULTS
The cohort included 380 patients with at least RMP-
and INH-resistant M. tuberculosis. Bacillary strains
from 356 (93.7%) patients were tested for at least one
SLI, and 352 (92.6%) for an FQ. A total of 33 (8.7%)
patients were classified as XDR-TB based on the DST
results, and 89 (23.4%) as pre-XDR-TB.
Table 1 shows lowDST capacity for later-generation
FQs (levofloxacin and moxifloxacin) and linezolid at
the participating centres in Europe. Bacilli from
patients with pre-XDR-TB showed .30% resistance
to any FQ and almost 70% to any SLI. Respectively
.90% and .80% of the tested XDR-TBM. tubercu-
losis strains showed phenotypic resistance to pyrazin-
amide (PZA) and ethambutol. Additional resistance to
prothionamide/ethionamide was high in bacilli from
both pre-XDR- (43%) and XDR-TB patients (49%).
DST against Group 5 drugs was rarely performed.
Previous anti-tuberculosis treatment and age ,45
years were independent risk factors for MDR-TB in
this cohort.5,6 Table 2 shows the results of the
Table 1 Resistance to first- and second-line anti-tuberculosis drugs in MDR-, pre-XDR- and XDR-TB patients at 23 Tuberculosis
Network European Trial sites in 16 countries in Europe
Drug
MDR-TB (n ¼ 258) Pre-XDR-TB (n ¼ 89) XDR-TB (n ¼ 33)
Total tested Resistant Total tested Resistant Total tested Resistant
n (%) n (%) n (%) n (%) n (%) n (%)
Group 1
Ethambutol 250 (96.9) 141 (56.4) 88 (98.9 52 (59.1) 33 (100) 27 (81.8)
Pyrazinamide 98 (38.0) 44 (44.9) 56 (62.9) 44 (78.5) 18 (54.5) 17 (94.4)
Streptomycin 247 (95.7) 218 (88.3) 86 (96.6) 83 (96.5) 31 (93.9) 30 (96.8)
Group 2
Any SLI 234 (90.7) NA 89 (100) 60 (67.4) 33 (100) 33 (100)
Amikacin 97 (37.6) NA 56 (62.9) 26 (46.4) 27 (81.8) 16 (59.3)
Capreomycin 171 (66.3) NA 67 (75.3) 26 (38.8) 28 (84.8 19 (67.9)
Kanamycin 189 (73.3) NA 72 (80.9) 44 (61.1) 27 (81.8) 24 (88.9)
Group 3
Any FQ 230 (89.1) NA 89 (100) 29 (32.6) 33 (100) 33 (100)
Levofloxacin 17 (6.6) NA 10 (11.2) 3 (30.0) 5 (15.2) 1 (20.0)
Moxifloxacin 39 (15.1) NA 23 (25.8) 8 (34.8) 11 (33.3) 9 (81.8)
Ofloxacin 209 (81.0) NA 82 (92.1) 23 (28.0) 33 (100) 33 (100)
Group 4
Cycloserin/terizidon 129 (50.0) 6 (4.7) 65 (73.0) 6 (9.2) 25 (75.8 11 (44.0
Ethionamide/prothionamide 234 (90.7) 65 (27.8) 87 (97.8) 38 (42.7) 33 (100) 16 (48.5)
PAS 193 (74.8) 6 (3.1) 69 (77.5) 7 (10.1) 29 (87.9) 9 (31.0)
Group 5
Amoxicillin/clavulanic acid 0 NA 0 NA 0 NA
Clarithromycin 12 (4.7) 3 (25.0) 2 (2.2) 0 3 (9.1) 0.0
Imipenem 0 NA 0 NA 0 NA
Linezolid 40 (15.5) 0 21 (23.6) 0 8 (24.2) 2 (25.0)
Meropenem 0 NA 1 (1.1) 1 (100) 0 NA
Clofazimine 0 NA 0 NA 0 NA
MDR-TB¼multidrug-resistant tuberculosis; XDR-TB¼ extensively drug-resistant TB; SLI¼ second-line injectable; NA¼not available; FQ¼ fluoroquinolone; PAS¼
para-aminosalicylic acid.
Beyond MDR-TB in Europe 1525
multinomial logistic regression analysis. None of the
risk factors were seen to have a predictive value with
regard to an increased level of drug resistance.
DISCUSSION
In this European cohort of patients infected with M.
tuberculosis strains and resistance to at least RMP
and INH, almost one quarter of infecting strains
showed additional resistance to either an SLI or an
FQ at the start of treatment (pre-XDR-TB), while
8.7% of the MDR-TB strains fulfilled our definition
for XDR-TB. PZA resistance testing was infrequently
performed in high proportions of resistance in M.
tuberculosis strains (44.9% for MDR-, 78.5% for
pre-XDR- and 94.4% for XDR-TB). These findings
challenge the current WHO recommendation, issued
in 2011, of treating all MDR-TB patients with PZA,
and limit the possible use of this drug in new regimens
currently under development.7,8
The importance of drug resistance in addition to
RMP and INH resistance in relation to treatment
success was recently highlighted in an analysis of
9153 MDR-TB patients. The study demonstrated the
association of in vitro susceptibility to first- and
second-line drugs with higher odds of treatment
success.9 Additional in vitro resistance, as observed in
this European cohort, is thus likely to increase the
frequency of treatment failure. This finding is
complicated by the fact that the risk of acquired drug
resistance during anti-tuberculosis treatment increas-
es substantially with increasing resistance to other
drugs in the regimen.10
Results from this observational cohort study
suggest that wider use of DST might reveal high
levels of second-line anti-tuberculosis drug resistance
in Europe, including a higher frequency of XDR-TB.
The combination of the low frequency of DSTagainst
second-line drugs, and the finding of high resistance
levels to those drugs when tested, might explain the
recently reported low treatment success rate for
MDR-TB in Europe.4 In agreement with the results
from the Preserving Effective TB Treatment Study
(PETTS), we did not find any association between
Table 2 Results of a multinomial logistic regression analysis with possible risk factors for increase in levels of M. tuberculosis drug
resistance
Variable
Predicted probabilities
OR (95%CI) P valueMDR-TB Pre-XDR-TB XDR-TB
Sex
Male 67.2 26.0 6.8
Female 69.0 24.7 6.3 0.92 (0.59–1.43) 0.720
Age ,45 years
No 68.3 25.1 6.6
Yes 67.8 25.5 6.7 1.02 (0.64–1.64) 0.921
Previous TB
No/unknown 67.2 26.0 6.8
Yes 68.6 25.0 6.4 0.94 (0.61–1.44) 0.773
Unemployment
No/unknown 69.2 24.6 6.2
Yes 65.8 27.0 7.2 1.17 (0.75–1.80) 0.491
Previous imprisonment
No/unknown 68.0 25.5 6.6
Yes 66.8 26.3 6.9 1.06 (0.48–2.31) 0.887
Current or previous homelessness
No/unknown 68.1 25.4 6.5
Yes 63.2 28.8 8.0 1.24 (0.45–3.42) 0.673
Intravenous drug user
No/unknown 67.7 25.7 6.6
Yes 71.3 23.1 5.7 0.84 (0.34–2.07) 0.708
HIV-infected
No/unknown 68.9 24.8 6.2
Yes 53.7 35.1 11.3 1.91 (0.88–4.16) 0.103
Hepatitis B-infected
No/unknown 68.5 25.1 6.4
Yes 55.3 34.0 10.7 1.76 (0.70–4.45) 0.235
Hepatitis C-infected
No/unknown 68.5 25.1 6.4
Yes 55.3 34.0 10.7 1.76 (0.69–4.45) 0.235
Diabetes
No/unknown 68.7 25.0 6.3
Yes 45.8 39.4 14.8 2.59 (0.90–7.45) 0.077
OR ¼ odds ratio; CI ¼ confidence interval; MDR-TB ¼ multidrug-resistant TB; XDR-TB ¼ extensively drug-resistant TB; TB ¼ tuberculosis; HIV ¼ human
immunodeficiency virus.
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selected risk factors and increasing levels of drug
resistance.10 Individual risk factors present for MDR-
TB could therefore well be indicative of underlying
pre-XDR- or XDR-TB, thus necessitating DST for
second-line drugs.
Our study has several limitations. Data were
derived from an international multicentre observa-
tional cohort study and not from routine drug
resistance surveillance. Although hospitals specialis-
ing in the care of MDR-/XDR-TB patients from 14 of
28 EU and 2 non-EU countries participated in the
study, the data may not be generalisable to all of
Europe. Selection bias due to the inclusion of only
MDR-TB cases who were severely ill is thought to be
limited, given the consecutive sampling approach and
the fact that MDR-/XDR-TB was treated in only a
few specialist centres in each country. For greater
representativeness of the data, we also performed
weighted analyses stratified by incidence based on the
sampling fraction and the expected number of
notified MDR-TB patients in the countries from
which patients were recruited. These results suggest
that, at the very least, frequencies of resistance
against second-line drugs might even have been
underestimated in our cohort (data not shown).
In conclusion, we identified a low frequency of
DST coverage for later-generation FQ and WHO
Class 5 anti-tuberculosis drugs, and a high frequency
of M. tuberculosis strains resistant to second-line
anti-tuberculosis drugs in addition to RMP and INH.
Our findings contribute to a better understanding of
the poor treatment outcomes in MDR-TB patients in
Europe,4 and argue against the use of standardised
drug regimens for MDR-TB treatment in this region.
Our results indicate the urgent need to scale up
molecular (genotypic) and phenotypic second-line
DST in Europe to obtain much needed results before
treatment start and to facilitate the use of appropriate
and effective regimens for patients with drug-resistant
TB.
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R E S U M E
L’e´mergence de la tuberculose (TB) pharmacore´sistante
est un de´fi vis-a`-vis de la lutte contre la TB en Europe.
Nous avons e´value´ les tests de sensitibilite´ aux
me´dicaments de deuxie`me ligne de Mycobacterium
tuberculosis provenant de patients atteints de TB
multire´sistante (TB-MDR), pre´-ultrare´sistante (TB pre´-
XDR) et TB-XDR dans 23 sites TBNET dans 16 pays
d’Europe. Plus de 30% des bacilles de patients atteints de
TB pre´-XDR ont de´montre´ une re´sistance a` toutes les
fluoroquinolones et a` presque 70% de tous les
me´dicaments de deuxie`me ligne injectables. Plus de
90% et plus de 80% respectivement des souches TB-
XDR teste´es ont de´montre´ une pharmacore´sistance
phe´notypique vis-a`-vis du pyrazinamide et de
l’e´thambutol. La pharmacore´sistance au
prothionamide/e´thionamide a e´te´ e´leve´e pour les
bacilles de patients atteints de TB pre´-XDR (43%) et
TB-XDR (49%).
R E S UM E N
La aparicio´n de tuberculosis (TB) farmacorresistente
representa un peligro en el control de la TB en Europa.
En el presente estudio se evaluaron dos pruebas de
sensibilidad de Mycobacterium tuberculosis a los
medicamentos de segunda lı´nea, en pacientes con TB
multidrogorresistente (TB-MDR), pre-extremadamente
drogorresistente (TB pre-XDR) y TB-XDR provenientes
de 23 centros del grupo TBNET en 16 paı´ses europeos.
Ma´s del 30% de los bacilos provenientes de los pacientes
con TB pre-XDR exhibio´ resistencia a todas las
fluoroquinolonas y cerca del 70% fue resistente a
todos los medicamentos inyectables de segunda lı´nea.
De las cepas causantes de TB-XDR estudiadas, ma´s del
90% presento´ resistencia a pirazinamida y ma´s del 80%
a etambutol. La farmacorresistencia a protionamida y
etionamida fue alta en los bacilos de pacientes con TB
pre-XDR (43%) y TB-XDR (49%).
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